Warning letter wave
This is one entry from the TitrateLab Vendor Graveyard, a dated, primary-source archive of peptide-market shutdowns, exit scams, and enforcement actions. Documented as December 10, 2024. Sources for this entry are named inline below and numbered in full on the parent archive page.
The FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research. All four were GLP-1-focused grey-market vendors. The letters asserted violations including marketing unapproved new drugs, misbranding, and in some cases direct human-use marketing with “research only” veneer.
Why it still matters: this was the first time the FDA sent multiple simultaneous warning letters at the RUO-vendor tier rather than at the compounding-pharmacy tier. Showed FDA was expanding enforcement from “compounders we can regulate” to “online vendors we want to shut down.” In the three months after this wave, Behemoth Labz removed peptides and injectables from its catalog; Limitless Life rebranded to Limitless Biotech; and the market broadly began pre-emptive catalog trimming ahead of the 2025 enforcement surge.
Primary sources: FDA MARCS-CMS warning letters; RAPS coverage of the Dec 2024 wave.